Alecta Tjanstepension Omsesidigt Boosts Stock Holdings in Stryker Corporation $SYK

Key Points

• Alecta Tjanstepension Omsesidigt raised its stake in Stryker by 6.4% during Q4 to 487,500 shares, worth about $171.3 million (roughly 0.13% of the company).
• Stryker missed quarterly expectations, reporting $2.60 EPS versus $2.98 expected and $6.02B revenue versus $6.34B expected, while setting FY2026 guidance of $14.90–15.10 EPS (analysts forecast ~14.97).
• Analyst sentiment is cautiously positive with a consensus "Moderate Buy" (16 Buys, 6 Holds) and an average target of $395.48, even as the stock trades near $292 and institutional ownership stands at about 77.09%.

Alecta Tjanstepension Omsesidigt raised its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 6.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 487,500 shares of the medical technology company's stock after purchasing an additional 29,200 shares during the period. Alecta Tjanstepension Omsesidigt owned 0.13% of Stryker worth $171,317,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $27,000. Strive Asset Management LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $30,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker during the 3rd quarter worth approximately $34,000. Copia Wealth Management raised its stake in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock worth $40,000 after acquiring an additional 69 shares in the last quarter. Finally, WPG Advisers LLC raised its stake in shares of Stryker by 156.8% during the 3rd quarter. WPG Advisers LLC now owns 113 shares of the medical technology company's stock worth $42,000 after acquiring an additional 69 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of several recent analyst reports. William Blair reiterated an "outperform" rating on shares of Stryker in a research note on Thursday, March 5th. Canaccord Genuity Group cut their price objective on shares of Stryker from $435.00 to $400.00 and set a "buy" rating on the stock in a report on Friday, May 1st. Leerink Partners assumed coverage on shares of Stryker in a report on Monday, April 13th. They set an "outperform" rating and a $410.00 price objective on the stock. Citigroup cut their price objective on shares of Stryker from $420.00 to $385.00 and set a "buy" rating on the stock in a report on Tuesday, April 7th. Finally, Evercore set a $355.00 price objective on shares of Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $395.48.

Stryker Trading Down 1.1%

Stryker stock opened at $292.13 on Thursday. Stryker Corporation has a 12 month low of $289.91 and a 12 month high of $404.87. The firm has a market cap of $111.88 billion, a PE ratio of 33.81, a P/E/G ratio of 1.86 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock's 50 day simple moving average is $342.12 and its two-hundred day simple moving average is $355.73.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period in the prior year, the business posted $2.84 EPS. Stryker's revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts anticipate that Stryker Corporation will post 14.97 earnings per share for the current year.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.